RAMP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RAMP is NOT a good buy right now for an impatient investor. The tape is still bearish (downtrend + weakening momentum), and heavy insider selling is a meaningful red flag. While fundamentals recently improved and options positioning skews bullish, there’s no Intellectia buy signal today and the chart suggests downside risk remains near-term. Best stance: HOLD/avoid new buys until price reclaims key resistance (~25.03–25.99) or momentum turns.
Trend/Momentum: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend. MACD: Histogram -0.13 and negatively expanding → downside momentum is strengthening, not stabilizing. RSI: RSI_6 = 23.3, which is oversold (not neutral) → could support a short-term bounce, but oversold can persist in downtrends. Key levels: Price 24.12 is sitting right on S1 (24.077). A clean break below S1 opens room toward S2 (23.487). Upside needs a reclaim of Pivot 25.032, then R1 25.987. Pattern-based short-term bias: Similar-pattern stats suggest mild drift lower next day (-0.25%) and next month (-1.51%), with only a small positive skew next week (+0.37%).
Intellectia Proprietary Trading Signals
on 2026-02-05 after hours could act as a catalyst if guidance/AI-data collaboration demand surprises to the upside (EPS est. 0.45).
Insiders are selling aggressively (selling amount up ~318.6% over the last month), often a near-term sentiment overhang.
Latest quarter: 2026/Q2. Growth: Revenue increased to $199.829M (+7.73% YoY), indicating continued top-line expansion. Profitability: Net income rose to $27.42M (+1483% YoY) and EPS to $0.42 (+1300% YoY), signaling a major earnings step-up versus the prior year. Quality/margins: Gross margin fell to 70.18% (-3.04% YoY), a cautionary note despite the sharp EPS improvement. Overall: Fundamentally improving, but margin compression and the current downtrend mean the market is not rewarding the story right now.
Recent analyst change: (2025-11-13) Morgan Stanley raised price target to $33 from $30 and maintained an Equal Weight rating. Wall Street pros: PT increase suggests improving confidence post-results and meaningful upside potential if growth/profitability persists. Wall Street cons: Equal Weight (not Buy) signals balanced risk/reward—execution and margin trajectory still need to prove out, aligning with the market’s currently bearish technical posture.
